| Literature DB >> 35505860 |
Mahitab Ghoneim1, Riham Eid1, Nashwa Hamdy1, Doaa Shokry1, Mohammed A Salem1, Ahmed El-Morsy1, Ali H Elmokadem1.
Abstract
Purpose: The outbreak of a new coronavirus is still spreading worldwide, affecting children and adults. However, COVID-19 in children shows distinctive characteristics in clinical and radiological presentation. We aimed to assess the diagnostic performance of chest CT and clarify the clinicoradiological CT features of COVID-19 among children with COVID-19. Material and methods: Adhering to PRISMA-DTA guidelines, we searched databases (PubMed, Google Scholar, and Web of Science) to identify relevant articles. The search keywords were: "Chest CT" AND "COVID-19" OR "coronavirus" OR "SARS-COV-2" AND "Children" OR "Pediatric". Published reports providing clinical and imaging findings of paediatric COVID-19 were included.Entities:
Keywords: COVID-19; SARS-CoV-2; chest CT; children; coronavirus; diagnostic performance
Year: 2022 PMID: 35505860 PMCID: PMC9047799 DOI: 10.5114/pjr.2022.114505
Source DB: PubMed Journal: Pol J Radiol ISSN: 1733-134X
Figure 1PRISMA 2009 flow diagram shows literature search and study selection
Included studies and demographic data of the subjects
| First author; date available online | Time window of the study | Study design | No. of children | Male, | Age (years) | Average hospital stay (days) | Reference | |
|---|---|---|---|---|---|---|---|---|
| Mean/median | Range | |||||||
| Chen | 18-Jan/11-Feb | Retrospective | 12 | 6 (50.0) | 14.5 | 9.3-15.8 | NA | [ |
| Chen | 11-Jan/12-Feb | Prospective | 31 | 13 (41.9) | 6.75 | 1.5-17.0 | NA | [ |
| Tang | 16-Jan/8-Feb | Retrospective | 26 | 9 | 6.9 ± 0.7 | 1.0-3.0 | 13.6 ±1.0 | [ |
| Li | 28-Jan/8-Feb | Retrospective | 5 | 4 | 1.1 ± 0.4 | 0.8-6.0 | 10.6 (1.0-14.0) | [ |
| Xu | 14-Jan/20-Feb | Prospective | 10 | 6 | 6.6 | 0.2-15.5 | NA | [ |
| Zheng | 1-Feb/10-Feb | Retrospective | 25 | 14 | 3 | 3.0-14.0 | NA | [ |
| Yu | 1-Feb/10-Feb | Retrospective | 82 | 51 | NA | 0-16.0 | 11.2 | [ |
| Sun | 24-Jan/24-Feb | Unclear | 8 | 6 | 5 | 0.2-15.0 | 18.5 | [ |
| Qiu | 17-Jan/1-Mar | Retrospective | 36 | 23 | 8.3 ± 3.5 | 1.0-16.0 | 14.0 (10.0-20.0) | [ |
| Su | 24-Jan/24-Feb | Retrospective | 9 | 3 | 5.2 | 0.9-9.0 | 14.0-21.0 | [ |
| Chen | 1-Feb/10-Mar | Retrospective | 10 | 5 | NA | 2.0-15.0 | 18.0 (2.0-26.0) | [ |
| Liu | NA | Unclear | 5 | 4 | 5.2 | 0.9-13.0 | 9.8 | [ |
| Li | 26-Jan/20-Feb | Retrospective | 8 | 3 | 2.5 | 1.0-5.0 | NA | [ |
| Liu | 7-Jan/13-Jan | Retrospective | 5 | 2 | 3 | 1.0-4.0 | 7.5 | [ |
| Chen | 25-Jan/15-Feb | Retrospective | 14 | 8 | 4.7 | 0.2-10.0 | NA | [ |
| Shen | 8-Jan/19-Feb | Retrospective | 9 | 3 | 8 | 1.0-12.0 | 15.3 | [ |
| Zhu | 24-Jan/22-Feb | Retrospective | 10 | 5 | 9.5 | 1.5-17.0 | NA | [ |
| Xie | 5-Feb/30-Mar | Retrospective | 13 | 7 | 16 | 10.0-18.0 | NA | [ |
| Qiu | 20-Jan/15-Mar | Retrospective | 25 | 9 | NA | 0-10.0 | 10.8 | [ |
| Tan | 27-Jan/10-Mar | Retrospective | 10 | 3 | 8.8 | 1.1-12.1 | NA | [ |
| Wu | 20-Jan/27-Feb | Retrospective | 74 | 44 | 6 | 0.1-15.1 | 11.0 (9.0-14.0) | [ |
| Du | 23-Jan/15-Feb | Retrospective | 14 | 6 | 6.2 | 0-16.0 | NA | [ |
| Xia | 21-Jan/14-Mar | Retrospective | 114 | 69 (60.5) | NA | NA | 13.0 | [ |
| Hua | NA/29-Feb | Retrospective | 43 | 26 (60.5) | 8.2 | 0.8-14.0 | NA | [ |
| Lu | 28-Jan/26-Feb | Unclear | 171 | 104 (60.8) | 6.7 | 0-15.0 | 20.2 (3.0-32.0) | [ |
| Song | 31-Jan/17-Mar | Unclear | 16 | 10 (62.5) | 8.5 | 1.0-14.0 | 15.6 | [ |
| Lu | 22-Jan/9-Feb | Retrospective | 9 | 5 (55.6) | 7.8 | 0.2-15.0 | NA | [ |
| Xiong | 21-Feb/20-Mar | Retrospective | 193 | 120 (62.2) | 3.6 | 0.2-10.2 | 12.0 (8.0-17.0) | [ |
Risk of bias and applicability of included studies
| Study [reference] | Risk of bias | Applicability | |||||
|---|---|---|---|---|---|---|---|
| Patient selection | Index test | Reference standard | Flow and timing | Patient selection | Index test | Reference standard | |
| Chen |
|
|
|
|
|
|
|
| Chen |
|
|
|
|
|
|
|
| Tang |
|
|
|
|
|
|
|
| Li |
|
|
|
|
|
|
|
| Xu |
|
|
|
|
|
|
|
| Zheng |
|
|
|
|
|
|
|
| Yu |
|
|
|
|
|
|
|
| Sun |
|
|
|
|
|
|
|
| Qiu |
|
|
|
|
|
|
|
| Su |
|
|
|
|
|
|
|
| Chen |
|
|
|
|
|
|
|
| Liu |
|
|
|
|
|
|
|
| Li |
|
|
|
|
|
|
|
| Liu |
|
|
|
|
|
|
|
| Chen |
|
|
|
|
|
|
|
| Shen |
|
|
|
|
|
|
|
| Zhu |
|
|
|
|
|
|
|
| Xie |
|
|
|
|
|
|
|
| Qiu |
|
|
|
|
|
|
|
| Tan |
|
|
|
|
|
|
|
| Wu |
|
|
|
|
|
|
|
| Du |
|
|
|
|
|
|
|
| Xia |
|
|
|
|
|
|
|
| Hua |
|
|
|
|
|
|
|
| Lu |
|
|
|
|
|
|
|
| Song |
|
|
|
|
|
|
|
| Lu |
|
|
|
|
|
|
|
| Xiong | ? |
|
|
|
|
|
|
– low risk of bias, – high risk of bias, ? – unclear
Pooled analysis of included studies regarding clinical, laboratory, and outcome features
| Factor | Number of studies | Pooled incidence | Total number of reported cases | Pooled proportion (%) | 95% CI | Q | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||||||
| Male sex | 28 | 568 | 987 | 55.9 | 51.8 | 59.9 | 35.868 | 25.80 | 0.118 | |
| Clinical status | ||||||||||
| Asymptomatic | 28 | 185 | 987 | 25.3 | 17.6 | 33.0 | 293.338 | 95.06 | < 0.001 | |
| Symptomatic | 27 | 807 | 975 | 76.9 | 69.2 | 84.7 | 264.928 | 96.19 | < 0.001 | |
| Clinical presentation | ||||||||||
| Fever | 27 | 474 | 807 | 64.6 | 58.0 | 71.2 | 77.998 | 66.69 | < 0.001 | |
| Cough | 27 | 472 | 807 | 58.5 | 50.4 | 66.6 | 16.285 | 79.45 | < 0.001 | |
| Sore throat | 27 | 110 | 807 | 12.3 | 5.6 | 1.9 | 226.902 | 95.94 | < 0.001 | |
| Rhinorrhoea | 27 | 63 | 807 | 6.8 | 3.8 | 9.7 | 67.528 | 73.07 | < 0.001 | |
| Sputum | 27 | 52 | 807 | 6.8 | 0.3 | 10.6 | 94.093 | 92.33 | < 0.001 | |
| Dyspnoea and tachypnoea | 27 | 69 | 807 | 6.0 | 2.8 | 9.2 | 79.537 | 76.69 | < 0.001 | |
| Diarrhoea | 27 | 47 | 807 | 6.2 | 3.6 | 8.8 | 56.707 | 67.24 | <0.001 | |
| Nausea and vomiting | 27 | 42 | 807 | 5.7 | 3.3 | 8.2 | 66.149 | 64.00 | < 0.001 | |
| Fatigue | 27 | 41 | 807 | 4.2 | 2.2 | 6.2 | 44.564 | 46.74 | 0.013 | |
| Headache | 27 | 21 | 807 | 2.4 | 1.0 | 3.8 | 24.638 | 34.23 | 0.540 | |
| Abdominal pain | 27 | 12 | 807 | 0.6 | 0.1 | 1.1 | 20.563 | 0 | 0.764 | |
| Constipation | 27 | 1 | 807 | 0.5 | 0 | 1.0 | 10.512 | 0 | 0.997 | |
| Clinical severity | ||||||||||
| Minimal | 21 | 121 | 494 | 19.5 | 12.9 | 26.2 | 87.594 | 74.73 | <0.001 | |
| Common | 21 | 289 | 494 | 49.3 | 38.7 | 59.9 | 133.489 | 83.18 | < 0.001 | |
| Severe | 22 | 19 | 576 | 3.0 | 1.6 | 4.3 | 18.882 | 0.21 | 0.593 | |
| Critical | 23 | 21 | 747 | 2.3 | 1.3 | 3.4 | 14.419 | 0.01 | 0.886 | |
| Laboratory investigations | ||||||||||
| Neutropaenia | 9 | 44 | 180 | 28.8 | 13.8 | 43.7 | 38.780 | 84.42 | < 0.001 | |
| Leucopaenia | 26 | 137 | 702 | 17.6 | 11.9 | 23.3 | 101.262 | 78.79 | < 0.001 | |
| Increased neutrophils | 11 | 47 | 195 | 14.6 | 5.1 | 24.0 | 48.171 | 77.11 | < 0.001 | |
| Lymphopaenia | 25 | 78 | 833 | 13.5 | 7.0 | 20.0 | 106.888 | 92.85 | < 0.001 | |
| Elevated CRP | 18 | 66 | 385 | 13.1 | 8.1 | 18.1 | 42.981 | 55.47 | < 0.001 | |
| Leukocytosis | 26 | 198 | 702 | 12.5 | 5.6 | 19.3 | 426.373 | 93.24 | < 0.001 | |
| Lymphocytosis | 27 | 87 | 873 | 10.1 | 4.2 | 16.0 | 180.790 | 96.92 | < 0.001 | |
| Thrombocytosis | 17 | 37 | 410 | 5.8 | 2.5 | 0.9 | 31.785 | 57.90 | 0.011 | |
| Comorbidities | ||||||||||
| CHD | 14 | 3 | 617 | 0.5 | 0 | 1.1 | 6.096 | 0 | 0.943 | |
| Leukaemia | 14 | 2 | 617 | 0.7 | 0.1 | 1.3 | 3.875 | 0 | 0.992 | |
| Nephroblastoma | 14 | 1 | 617 | 0.5 | 0 | 1.1 | 4.469 | 0 | 0.985 | |
| Hydronephrosis | 14 | 1 | 617 | 0.7 | 0.1 | 1.3 | 3.261 | 0 | 0.997 | |
| Asthma | 14 | 1 | 617 | 0.5 | 0 | 1.1 | 4.354 | 0 | 0.987 | |
| Duplicate kidney | 14 | 1 | 617 | 0.5 | 0 | 1.1 | 4.354 | 0 | 0.987 | |
| Outcomes | ||||||||||
| Discharge | 23 | 637 | 745 | 79.9 | 69.6 | 90.2 | 686.407 | 98.83 | < 0.001 | |
| Hospitalized | 23 | 107 | 745 | 20 | 9.7 | 30.3 | 685.228 | 98.83 | < 0.001 | |
| Death | 24 | 1 | 759 | 0.8 | 0.2 | 1.4 | 6.487 | 0 | 1 | |
CRP – C-reactive protein, CHD – congenital heart disease
Pooled analysis of included studies regarding radiological findings
| Factor | Number of studies | Pooled incidence | Total number of CTs performed | Pooled proportion (%) | 95% CI | Q | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||||||
| CT findings | ||||||||||
| Normal | 28 | 329 | 987 | 34.2 | 26.4 | 41.9 | 294.532 | 88.16 | < 0.001 | |
| Abnormal | 28 | 658 | 987 | 65.8 | 58.1 | 73.6 | 294.532 | 88.16 | < 0.001 | |
| Patterns of abnormal CT | ||||||||||
| GGO | 23 | 237 | 591 | 52.6 | 40.5 | 64.7 | 447.265 | 91.85 | < 0.001 | |
| Patches | 22 | 101 | 554 | 24.5 | 11.5 | 37.5 | 654.722 | 99.4 | < 0.001 | |
| Consolidation | 21 | 58 | 538 | 11.9 | 4.5 | 19.2 | 127.832 | 97.36 | < 0.001 | |
| Nodules | 22 | 17 | 554 | 2.8 | 0.7 | 4.9 | 35.763 | 57.3 | 0.023 | |
| Interlobular septal thickening | 22 | 6 | 554 | 0.7 | 0 | 1.4 | 13.052 | 0 | 0.907 | |
| Reticular pattern | 23 | 2 | 591 | 0.7 | 0 | 1.3 | 9.098 | 0 | 0.993 | |
| Bronchopneumonia | 22 | 9 | 554 | 0.6 | 0 | 1.3 | 24.998 | 0.85 | 0.247 | |
| GGO mixed with consolidation | 22 | 6 | 554 | 0.6 | 0 | 1.3 | 12.143 | 0 | 0.936 | |
| Halo sign | 22 | 6 | 554 | 0.6 | 0 | 1.3 | 15.160 | 0 | 0.815 | |
| Pleural effusion | 22 | 6 | 554 | 0.6 | 0 | 1.3 | 22.390 | 0.53 | 0.377 | |
| Air bronchogram | 22 | 2 | 554 | 0.6 | 0 | 1.3 | 10.026 | 0 | 0.979 | |
| White lung | 23 | 1 | 591 | 0.6 | 0 | 1.3 | 8.876 | 0 | 0.994 | |
| LNs | 22 | 1 | 554 | 0.6 | 0 | 1.3 | 0.991 | 0 | 0.991 | |
| Laterality | ||||||||||
| Unilateral | 19 | 364 | 594 | 56.8 | 47.6 | 66 | 79.802 | 79.07 | < 0.001 | |
| Bilateral | 19 | 227 | 594 | 42.1 | 33.2 | 50.9 | 70.692 | 79.91 | < 0.001 | |
| Side | ||||||||||
| Right | 6 | 29 | 85 | 32 | 20 | 43.9 | 7.018 | 27.56 | 0.219 | |
| Left | 6 | 19 | 85 | 21.5 | 12.9 | 30.1 | 1.613 | 0 | 0.900 | |
| Axial distribution | ||||||||||
| Peripheral | 6 | 29 | 76 | 44.1 | 23.8 | 54.4 | 15.742 | 69.16 | 0.008 | |
| Peribronchovascular | 3 | 4 | 18 | 20.3 | 2.7 | 37.9 | 1.059 | 0 | 0.589 | |
| Lobar distribution | ||||||||||
| RLL | 4 | 52 | 104 | 49.6 | 40.1 | 59.1 | 2.551 | 0 | 0.466 | |
| LLL | 4 | 50 | 104 | 41.9 | 26 | 57.9 | 4.21 | 37.24 | 0.24 | |
| RUL | 4 | 39 | 104 | 37.4 | 28.1 | 46.7 | 0.532 | 0 | 0.912 | |
| LUL | 4 | 31 | 104 | 29.2 | 20.5 | 37.8 | 1.533 | 0 | 0.675 | |
| RML | 4 | 25 | 104 | 18.1 | 6.2 | 30 | 4.824 | 42.53 | 0.185 | |
| Number of lobes affected | ||||||||||
| 1 lobe | 5 | 50 | 111 | 51.7 | 35.6 | 67.9 | 6.942 | 43.52 | 0.139 | |
| 2 lobes | 5 | 38 | 111 | 32.4 | 22.8 | 42 | 3.053 | 5.98 | 0.549 | |
| 3 lobes | 5 | 10 | 111 | 8.9 | 3.7 | 14.2 | 1.080 | 0 | 0.897 | |
| 4 lobes | 5 | 5 | 111 | 5.9 | 1.6 | 10.3 | 0.192 | 0 | 0.996 | |
| 5 lobes | 5 | 7 | 157 | 7 | 2.3 | 11.7 | 0.615 | 0 | 0.961 | |
CT – computed tomography, GGO – ground glass opacity, LNs – lymph nodes, RLL – right lower lobe, LLL – left lower lobe, RUL – right upper lobe, LUL – left upper lobe, RML – right middle lobe
Figure 2A) Axial chest computed tomography (CT) images for a newborn with mother having COVID-19 proven by RT-PCR show peripheral ground glass opacities are noted bilaterally with posterior predominance. B) Axial and coronal chest CT images for 10-year-old girl with COVID-19 proven by RT-PCR show single unilateral centrally located ground glass opacity in the left lung. C) Axial chest CT images for 8-year-old boy with COVID-19 proved by RT-PCR show bilateral central and peripheral ground glass opacities with right middle lobe small consolidation. D) Axial chest CT images for another 8-yearold boy with COVID-19 proved by RT-PCR show right anterior reticular subpleural bands with bilateral ground glass opacities
Figure 3Forest plot shows sensitivity of computed tomography in all patients, symptomatic, and asymptomatic patients, respectively. Red circles indicate sensitivity from selected studies, and size reflects statistical weight. Horizontal lines indicate 95% confidence interval (CI) of each included study. Dashed line represents overall pooled estimate from meta-analysis, and diamond represents 95% CI of overall frequency
Figure 4A) Forest plot shows specificity of computed tomography (CT) in symptomatic patients. Red circles indicate specificity from selected studies, and size reflects statistical weight. Horizontal lines indicate 95% confidence interval (CI) of each included study. Dashed line represents overall pooled estimate from meta-analysis, and diamond represents 95% CI of overall frequency. B) Symmetric ROC curves for CT sensitivity and specificity of CT among symptomatic patients. Area under the curve is estimated to be 0.682